Enfortumab Biosimilar - Anti-PVRL4 mAb - Research Grade
Source
CAS 1346452-25-2
Species
Homo sapiens
Expression system
Mammalian cells
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery lead time in business days
3-5 days if in stock; 3-5 weeks if production needed
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Enfortumab,AGS-22CE,AGS-22M,AGS-22M6E,unconjugated:AGS-22C3 or AGSM6,PVRL4,anti-PVRL4
Reference
PX-TA1333
Note
For research use only. Not suitable for human use.
Isotype
IgG1-kappa
Description of Enfortumab Biosimilar - Anti-PVRL4 mAb - Research Grade
General information on Anti-PVRL4[Homo sapiens] (Enfortumab) Monoclonal Antibody
Enfortumab is a human monoclonal antibody that targets Nectin-4. It has been used as an antibody drug conjugate (ADC), Enfortumab vedotin to treat patients with advanced, treatment-resistant urothelial cancers.It has been marketed under the tradename Padcev.
SDS-PAGE for Enfortumab Biosimilar - Anti-PVRL4 mAb
Enfortumab Biosimilar - Anti-PVRL4 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Enfortumab Biosimilar – Anti-PVRL4 mAb – Research Grade binds to Human NECTIN4-PVRL4 recombinant protein in indirect ELISA Assay
Immobilized Human NECTIN4-PVRL4 recombinant protein (cat. No.PX-P6108) at 0.5µg/mL (100µL/well) can bind to Enfortumab Biosimilar – Anti-PVRL4 mAb – Research Grade (cat. No. PX-TA1333) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Enfortumab Biosimilar – Anti-PVRL4 mAb – Research Grade” Cancel reply
Reviews
There are no reviews yet.